Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

In development
Reference number: GID-TA10726
Expected publication date: 13 May 2026

Documents

Documents created during the development process.

Draft guidance

Draft guidance
Draft consultation document (online commenting)
Draft guidance (downloadable version) (PDF 231 KB)

Published:

09 January 2026
Equality impact assessment (downloadable version) (PDF 124 KB)

Published:

09 January 2026
Committee papers (PDF 7.19 MB)

Published:

09 January 2026
Public committee slides (PDF 1.31 MB)

Published:

09 January 2026

Invitation to participate

Final scope (PDF 120 KB)

Published:

13 May 2025
Final stakeholder list (PDF 122 KB)

Published:

13 May 2025
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 191 KB)

Published:

13 May 2025
Equality impact assessment (scoping) (PDF 109 KB)

Published:

13 May 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3843

Draft matrix post referral (PDF 91 KB)

Published:

17 March 2025
Draft scope post referral (PDF 105 KB)

Published:

17 March 2025